Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomatrix (BXM) Looking Great -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (557)	3/8/2000 7:13:00 AM
From: Greg Jung	Read Replies (1) \| Respond to of 569

Maybe they've got enough insiders and other holders on board. All they need is to get some analysts to say a few words and the point will become moot. Of course, there are no guarantees but this looks close. BioMatrix shareholders will have the option of receiving $37 in cash or one share of Genzyme Biosurgery for each BioMatrix share. The cash portion of the transaction will be about $245 million, the companies said.

To: dalroi who wrote (557)	3/10/2000 11:28:00 AM
From: Greg Jung	Read Replies (1) \| Respond to of 569

If the cash is oversubscribed, cash+stock will be alloted. As price drops, chance of oversubscription increases, making the stock less attractive, etc. GZSP reported results so sold off (to buy more JDSU, I suppose). Ouch!

To: dalroi who wrote (557)	3/20/2000 2:23:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 569

cbs.marketwatch.com Screamers Collateral Therapeutics rises on upbeat study By Stephanie O'Brien, CBS MarketWatch Last Update: 2:04 PM ET Mar 20, 2000 NewsWatch NEW YORK (CBS.MW) -- Shares of Collateral Therapeutics rose more than 60 percent Monday after the company said its Generx drug was safe and effective in an early stage trial. Shares of Collateral Therapeutics (CLTX: news, msgs) rose 17 3/8 to 43 1/8 in recent trading. Results of Collateral's Phase I/II trial of Generx in patients with chest pain showed that the drug was safe, well-tolerated and effective at multiple doses, the company said. (snip)